Brands should look to their agencies to be a true data-driven business partner, not just a creative partner, writes Kevin Troyanos.
A potential rush of treatment options on the horizon for non-alcoholic steatohepatitis will require skillful maneuvering in this likely lucrative but uncharted therapeutic market.
The Ipsos Healthcare Oncology Centre of Excellence's Jackie Ilacqua & Valerie Wriede trace the evolution of cancer treatment and drill down into the latest developments currently redefining the landscape, together with those on the horizon.
With the NASH pipeline filling up fast, Mariel Metcalfe looks at what pharma companies need to do to ensure their products do not end up as also-rans in this dynamic new market segment.
Today’s model requires a fourth partner-the systems integrator
Mastering digital business strategies and tactics will enable life sciences companies to supercharge innovation and speed therapy discovery, patient centric-practices and improved health outcomes, writes Bhaskar Sambasivan.
MilliporeSigma’s Stephen Wing, head of Analytical and Logistical Services, discusses the ways in which digital transformation and data transparency dramatically enhance supply chains, and how manufacturers are using the company’s eMERGE™ platform to improve overall efficiencies.
Outlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.
Outlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.
Brenda Gleason discusses the current health policy landscape and how future pharmacists can be healthcare leaders during a lecture at University of North Carolina Eshelman School of Pharmacy.
Ed Gudaitis Allergan VP and Country Manager, Canada, explains how embracing disruption is his secret to success.
This article explores the difficult nature of developing drugs for rare diseases and discusses what a pharmaceutical executive can actively do to help increase success.
Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, but the future for this market is still uncertain, writes Harriet Kozak.
Before entering into risk-sharing agreements, manufacturers must understand the challenges and implications, writes Kimberly E. White.
Webinar Date/Time: Wednesday, October 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
John Sattler offers some tips on engaging executive and professional recruiters.
If HEOR teams don’t clearly and concisely define themselves, their discipline, and their mission, they risk failure and irrelevance. A thoughtful communications program aimed at colleagues will win them due recognition of the value they bring, a say in key business decisions, and ongoing relevance.
is spectacular science enough to guarantee success for new medicines?
Abigail Bernardi explains how a better understanding of connections among practitioners on care teams helps sales reps build relationships while benefitting a company’s marketing efforts.
The GAIN Act creates a process for the Qualified Infectious Disease Product (QIDP) designation, which provides a range of incentives for developing antimicrobial therapies for combating resistant organisms. But while the program has been successful in driving innovation, commercial viability remains a question.
Mark Bouch, Stephen Bungay, and David Roblin outline how the technique of "mission command", a military approach to setting direction and executing strategy in the pharmaceutical industry, has developed over the last ten years.
Paul Meade and Mark Schoeman describe the determining factor driving effective relationships between medical science liaisons and key opinion leaders.
The Chinese government's “Healthy China” plan presents an unprecedented opportunity for the US healthcare industry and its investors, writes Steven Shill.